Appili Therapeutics Inc experienced a remarkable surge in its stock price, closing up 50% yesterday.
In yesterday's trading session, Appili Therapeutics Inc (APLI.TO) saw a significant increase in its stock price, closing at CA$0.01. This surge comes amid ongoing developments in the biopharmaceutical sector, particularly concerning its lead product, LIKMEZ® (ATI-1501).
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$1.99M
52W high
$0.04
52W low
$0.01
1W change
+50.00%
Beta
-0.21
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 900.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+900.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
207.3%
Annualized
90-Day Vol
222.9%
Annualized
Trend (90d)
+0.0%
Annualized drift
90d Mean
C$0.02
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.02 | C$0.01 – C$0.03 |
| 60 trading days | C$0.02 | C$0.01 – C$0.04 |
| 90 trading days | C$0.02 | C$0.00 – C$0.05 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: The sharp rise in Appili's stock price reflects growing investor confidence, likely driven by the company's recent operational milestones and funding efforts.
Stock Price Soars by 50%
Appili's stock price jumped from CA$0.0067 to CA$0.01, reflecting a significant increase in market interest and trading activity.
Bull case
Appili's recent announcement about its fiscal year 2026 results highlighted commercial progress for LIKMEZ® in the U.S. market, which likely boosted investor sentiment. The US$40 million NIAID award supporting the advancement of VXV-01 through Phase 1 trials also shows strong institutional backing.
Bear case
Despite the positive movement, investors should stay cautious. The termination notice from the NIAID regarding the VXV-01 program raises concerns about the company's future funding and project viability. Additionally, with a market cap of just CA$1.98 million, Appili remains a high-risk investment.
Market Performance Overview
Advertisement
Appili Therapeutics Inc's stock price experienced a notable increase of 50% during yesterday's trading session, closing at CA$0.01. This surge is particularly impressive given the company's small market capitalization of CA$1.98 million, which often leads to heightened volatility in its stock price.
Recent Developments and Investor Sentiment
The increase in Appili's stock can be attributed to recent announcements regarding its fiscal year 2026 financial results, showcasing commercial progress for its lead product, LIKMEZ®. Furthermore, the US$40 million award from NIAID to support the VXV-01 program has likely bolstered investor confidence, despite the recent termination notice for the VXV-01 contract.
Looking Ahead
As Appili Therapeutics continues to navigate the complexities of the biopharmaceutical landscape, investors should watch for further updates on its product development and funding initiatives. The company's ability to capitalize on recent momentum will be crucial for its long-term success.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
